EBS — Emergent BioSolutions Share Price
0.000.00%
Last trade - 00:00- $251.04m
- $815.24m
- $1.04bn
- 68
- 90
- 61
- 85
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 4.71 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.52 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 7.01 | ||
| Price to Sales | 0.24 | ||
| EV to EBITDA | 33.41 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.88% | ||
| Return on Equity | -33.67% | ||
| Operating Margin | -8.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,555.4 | 1,773.6 | 1,117.5 | 1,049.3 | 1,043.6 | 825 | 1,195 | -1.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +507.24 | -26.92 | n/a | n/a | n/a | n/a | +102.67 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Directors
- Fuad El-Hibri CHM (63)
- Robert Kramer PRE (63)
- Richard Lindahl CFO (57)
- Adam Havey COO (50)
- Katherine Strei CHO (59)
- Atul Saran EVP (47)
- Sean Kirk EVP (46)
- Karen Smith EVP (53)
- Ronald Richard LED (65)
- Marvin White DRC (59)
- Zsolt Harsanyi IND (77)
- Jerome Hauer IND (69)
- George Joulwan IND (81)
- Louis Sullivan IND (87)
- Kathryn Zoon IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 19th, 2003
- Public Since
- November 15th, 2006
- No. of Shareholders
- 41
- No. of Employees
- 900
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 54,337,026
- Address
- 300 Professional Dr, GAITHERSBURG, 20879
- Web
- https://emergentbiosolutions.com/
- Phone
- +1 2406313200
- Contact
- Richard Lindahl
- Auditors
- Ernst & Young LLP
Upcoming Events for EBS
Q1 2025 Emergent BioSolutions Inc Earnings Release
Emergent BioSolutions Inc Annual Shareholders Meeting
Q2 2025 Emergent BioSolutions Inc Earnings Release
Similar to EBS
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
What is the Emergent BioSolutions share price?
As of Today at 20:25 UTC, shares in Emergent BioSolutions are trading at $4.62. This share price information is delayed by 15 minutes.
How has the Emergent BioSolutions share price performed this year?
Shares in Emergent BioSolutions last closed at $4.62 and the price had moved by +143.16% over the past 365 days. In terms of relative price strength the Emergent BioSolutions share price has outperformed the S&P500 Index by +128.64% over the past year.
What are the analyst and broker recommendations for Emergent BioSolutions?
The overall consensus recommendation for Emergent BioSolutions is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Emergent BioSolutions dividend yield?
Emergent BioSolutions does not currently pay a dividend.
Does Emergent BioSolutions pay a dividend?
Emergent BioSolutions does not currently pay a dividend.
When does Emergent BioSolutions next pay dividends?
Emergent BioSolutions does not currently pay a dividend.
How do I buy Emergent BioSolutions shares?
To buy shares in Emergent BioSolutions you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Emergent BioSolutions?
As of the previous close price of $4.62, shares in Emergent BioSolutions had a market capitalisation of $251.04m.
Where are Emergent BioSolutions shares listed?
Here are the trading details for Emergent BioSolutions:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: EBS
What kind of share is Emergent BioSolutions?
Based on an overall assessment of its quality, value and momentum Emergent BioSolutions is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Emergent BioSolutions share price forecast for 2025?
The analyst consensus target price for shares in Emergent BioSolutions is $13.50. That is 192.21% above the last closing price of $4.62.
Analysts covering Emergent BioSolutions currently have a consensus Earnings Per Share (EPS) forecast of $0.75 for the next financial year.
Find out moreWhat is the trend in the Emergent BioSolutions share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Emergent BioSolutions. Over the past six months, its share price has underperformed the S&P500 Index by -45.24%.
As of the last closing price of $4.62, shares in Emergent BioSolutions were trading -46.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Emergent BioSolutions PE Ratio?
The Emergent BioSolutions PE ratio based on its reported earnings over the past 12 months is 4.71. The shares last closed at $4.62.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Emergent BioSolutions?
Emergent BioSolutions' management team is headed by:
- Fuad El-Hibri - CHM
- Robert Kramer - PRE
- Richard Lindahl - CFO
- Adam Havey - COO
- Katherine Strei - CHO
- Atul Saran - EVP
- Sean Kirk - EVP
- Karen Smith - EVP
- Ronald Richard - LED
- Marvin White - DRC
- Zsolt Harsanyi - IND
- Jerome Hauer - IND
- George Joulwan - IND
- Louis Sullivan - IND
- Kathryn Zoon - IND